Baidu
map

Sci Rep:磨玻璃样结节性肺腺癌的基因组改变

2018-05-19 xiangting MedSci原创

EGFR、IDH2、TP53、PTEN、EPHB4和BRAF被推定为磨玻璃样结节性肺腺癌的驱动突变。

磨玻璃样结节性肺腺癌的深入分子发病机制尚不清楚。这项研究的目的是确定磨玻璃样结节性肺腺癌的基因组改变,并调查在这些肿瘤中是否可以检测到病毒转录物。

纳入9名纯实性(n=4)和部分实性(n=5)磨玻璃样结节性腺癌患者。其中6名为女性,中位年龄为58岁。研究人员进行了有针对性的外显子测序和RNA测序。通过有针对性的外显子测序发现EGFR(n=10)、IDH2(n=2)、TP53(n=1)、PTEN(n=1)、EPHB4(n=1)和BRAF(n=1)为驱动突变。与正常组织比较,包括NOTCH4和TGFBR3表达在内的血管生成相关基因在腺癌组织中显著下调(NOTCH4和TGFBR3的调整P值均<0.001)。另外,在4例肺腺癌中发现了5个新的融合基因座。然而,在肿瘤中未检测到显著的病毒相关转录物。

总之,EGFR、IDH2、TP53、PTEN、EPHB4和BRAF被推定为磨玻璃样结节性肺腺癌的驱动突变。4个肿瘤中发现了5种新的融合基因。病毒似乎不涉及磨玻璃样结节性肺腺癌的肿瘤生成。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693565, encodeId=c2b51693565f5, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Thu Nov 15 10:59:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801427, encodeId=49bf180142ebe, content=<a href='/topic/show?id=4584e3823f7' target=_blank style='color:#2F92EE;'>#磨玻璃样结节性肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73823, encryptionId=4584e3823f7, topicName=磨玻璃样结节性肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Jul 07 16:59:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801421, encodeId=347418014215f, content=<a href='/topic/show?id=1baee38220a' target=_blank style='color:#2F92EE;'>#磨玻璃样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73822, encryptionId=1baee38220a, topicName=磨玻璃样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 15 09:59:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316858, encodeId=32f0316858a4, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:04:29 CST 2018, time=2018-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693565, encodeId=c2b51693565f5, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Thu Nov 15 10:59:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801427, encodeId=49bf180142ebe, content=<a href='/topic/show?id=4584e3823f7' target=_blank style='color:#2F92EE;'>#磨玻璃样结节性肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73823, encryptionId=4584e3823f7, topicName=磨玻璃样结节性肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Jul 07 16:59:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801421, encodeId=347418014215f, content=<a href='/topic/show?id=1baee38220a' target=_blank style='color:#2F92EE;'>#磨玻璃样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73822, encryptionId=1baee38220a, topicName=磨玻璃样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 15 09:59:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316858, encodeId=32f0316858a4, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:04:29 CST 2018, time=2018-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693565, encodeId=c2b51693565f5, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Thu Nov 15 10:59:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801427, encodeId=49bf180142ebe, content=<a href='/topic/show?id=4584e3823f7' target=_blank style='color:#2F92EE;'>#磨玻璃样结节性肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73823, encryptionId=4584e3823f7, topicName=磨玻璃样结节性肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Jul 07 16:59:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801421, encodeId=347418014215f, content=<a href='/topic/show?id=1baee38220a' target=_blank style='color:#2F92EE;'>#磨玻璃样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73822, encryptionId=1baee38220a, topicName=磨玻璃样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 15 09:59:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316858, encodeId=32f0316858a4, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:04:29 CST 2018, time=2018-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693565, encodeId=c2b51693565f5, content=<a href='/topic/show?id=cb16e883013' target=_blank style='color:#2F92EE;'>#结节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78830, encryptionId=cb16e883013, topicName=结节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8429436174, createdName=crystal0572, createdTime=Thu Nov 15 10:59:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801427, encodeId=49bf180142ebe, content=<a href='/topic/show?id=4584e3823f7' target=_blank style='color:#2F92EE;'>#磨玻璃样结节性肺腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73823, encryptionId=4584e3823f7, topicName=磨玻璃样结节性肺腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Jul 07 16:59:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801421, encodeId=347418014215f, content=<a href='/topic/show?id=1baee38220a' target=_blank style='color:#2F92EE;'>#磨玻璃样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73822, encryptionId=1baee38220a, topicName=磨玻璃样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 15 09:59:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316858, encodeId=32f0316858a4, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:04:29 CST 2018, time=2018-05-20, status=1, ipAttribution=)]
    2018-05-20 kafei

    学习学习谢谢分享

    0

相关资讯

CLIN CANCER RES:FAM198B抑制肺腺癌转移延长患者生存

肺腺癌是最常见的恶性肿瘤,患者预后往往较差。对肿瘤转移机制的深层次理解有助于寻找转移相关基因辅助肺癌的诊断和治疗。CLIN CANCER RES近期发表了一篇文章进行这一研究

Sci Rep:吉非替尼治疗的晚期肺腺癌中自噬核心基因变异的临床意义

自噬核心基因变异体在吉非替尼治疗中显示出潜在的临床意义,尤其是在晚期肺腺癌患者中。

Transl Cancer Res:LncRNA NKILA在肺腺癌组织中高表达,并提示不良预后,可能为肺腺癌的诊疗提供新靶点!

在华中科技大学同济医学院附属同济医院呼吸与危重症医学科熊维宁教授团队支持下,「lncRNA NKILA的表达与肺鳞癌及肺腺癌患者预后的关系:基于TCGA数据库的分析」于2018年2月发表于Translational Cancer Research杂志。付博华为本文第一作者,陶玉为通讯作者。

病例分享:二次活检那些事——组织活检指导肺腺癌患者精准靶向治疗

根据患者病情进展情况,积极开展二次、甚至多次组织活检,解析敏感突变与耐药突变,能够帮助医生准确掌握患者的基因突变情况,从而为患者选择最合适的个体化靶向治疗。

PLos One:S100A16异常表达可作为非小细胞肺腺癌不良生存率的独立预后指标

S100A16表达异常可能受其DNA低甲基化调节,并可作为LUAD中不良OS和RFS的独立预后指标。

Cell Metab:肺癌免疫疗法,这类血检预示更有效

免疫疗法是癌症治疗领域的重大突破。已经上市的免疫检查点抑制剂在包括肺癌在内的多种癌症患者身上可以产生出色的疗效,但是并不是所有癌症患者都会对这些疗法产生反应。日前澳大利亚沃尔特和伊丽莎霍尔医学研究所 (Walter and Eliza Hall Institute of Medical Research) 的研究人员发现一种基因突变组合是导致特定侵袭性非常强的肺癌产生的原因,而且他们的研究结果表明

Baidu
map
Baidu
map
Baidu
map